Analyst Research

Analyst Viewpoints on Price Reaction History: Bristol-Myers Squibb Co (NYSE:BMY)

Bristol-Myers Squibb Co (NYSE:BMY) shares traded -0.64% during the most recent session the stock exchanged hands 17.28M shares versus average trading capacity of 8.70M shares, yielding a market cap of $92.60B. Wall Street analysts covering the stock are projecting that the stock will reach $56.33 within the next 52-weeks. The mean target projections are based on 21 opinions, the mean target was last revised on 05/01/17.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Bristol-Myers Squibb Co (NYSE:BMY) high price target of $68.00 and with a conservative view have low price target of $40.00 with a standard deviation of $5.64. If seeing target price from optimistic overview then it has a 22 percent upside potential from the latest closing price of $55.95.

Bristol-Myers Squibb Co (NYSE:BMY) “Upgraded” by Jefferies in a research note issued to investors on Dec-19-16 from Hold to Buy.

Additionally on Oct-28-16 Bristol-Myers Squibb Co (NYSE:BMY) was “Reiterated” by Deutsche Bank as Hold from $59 to $52 and on Sep-09-16 the stock was “Reiterated” by Barclays as Equal Weight from $75 to $65. Furthermore on Aug-11-16 the stock was “Downgraded” by Berenberg from Buy to Hold.

On the other hand the company has Relative Strength Index (RSI 14) of 62.98 along with Average True Range (ATR 14) of 0.87, Consequently Bristol-Myers Squibb Co (NYSE:BMY) weekly and monthly volatility is 2.03%, 1.43% respectively. The company’s beta value is at 1.08.

In terms of Buy, Sell or Hold recommendations, Bristol-Myers Squibb Co (NYSE:BMY) has analysts’ mean recommendation of 2.40. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

Analysts who have weighed in on projected earnings growth are expecting that Bristol-Myers Squibb Co (NYSE:BMY) will report earnings of $0.7 for the current quarter, however the company’s high EPS estimates are $0.74 and low estimates are $0.67. However the company reported $0.69 earnings per share for the same quarter during last year.

Previously Bristol-Myers Squibb Co (NYSE:BMY) reported $0.84 earnings per share (EPS) for the quarter on 4/27/2017 Before Market Open, beating the consensus estimate of $0.72 by $0.12. The company posted an earnings surprise of 16.67%.

While considering growth estimates of the company, it has next quarter growth estimates of -3.90% whereas during current quarter it has 1.40% estimations over growth, comparing to the estimations of 3.20% during current year and 7.20% for next year. Past 5 years growth of Bristol-Myers Squibb Co (NYSE:BMY) observed at 5.73%, looking forward for the next 5 years it has a strong prediction of 8.85% over growth.

Bristol-Myers Squibb Co (NYSE:BMY) revenue estimates for the current quarter are $4.95B according to 14 number of analysts, for the current quarter the company has high revenue estimates of $5.1B in contradiction of low revenue estimates of $4.79. For the current year the company’s revenue estimates are $19.86B compared to low analyst estimates of $19.29B and high estimates of $20.52B according 21 number of analysts.

Currently Bristol-Myers Squibb Co (NYSE:BMY) shares owned by insiders are 0.20%, whereas shares owned by institutional owners are 73.40%. However the six-month change in the insider ownership was recorded -5.01%, as well as three-month change in the institutional ownership was recorded -0.14%.

Bristol-Myers Squibb Co (NYSE:BMY) trading -25.93% away from its 52 week high of $75.54 and +22.49% far from the stock’s low point over the past 52 weeks, which was $45.68. The stock hit its 52-week high on 07/15/16, and 52-week low on 01/26/17. The company’s trailing twelve month income is 4.46B dollars and is paying 2.79% dividend yield annually.

Bristol-Myers Squibb Co (NYSE:BMY) trailing twelve month revenues are $19.43B, whereas its price to sales ratio for the same period is 4.82. Its book value per share for the most recent quarter is $9.66 while its price to book ratio for the same period is 5.79, as for as the company’s cash per share for the most recent quarter is $3.79, however its price to cash per share ratio for the same period is 14.75. The stock has a current PEG ratio of 2.37 where as its trailing twelve month P/E ratio is 21.06.

Previous ArticleNext Article